Peter Rieckmann
Impact in
-
- Multiple Sclerosis Research Studies
-
- Polyomavirus and related diseases
Papers in
-
- Multiple Sclerosis Research Studies 9
- Systemic Sclerosis and Related Diseases 1
- Genetics 4
- Chronic Lymphocytic Leukemia Research 4
- Co-authors
- Klaus V. Toyka (2 shared papers)Heinz Wiendl (1 shared paper)Ralf Gold (1 shared paper)Reinhard Hohlfeld (1 shared paper)Mathias Mäurer (1 shared paper)Philipp Gulde (2 shared papers)Sven G. Meuth (1 shared paper)Mike P. Wattjes (1 shared paper)
- Journals
- Stroke (1 paper)JMIR Rehabilitation and Assistive Technologies (1 paper)Journal of Neurology (1 paper)Expert Opinion on Pharmacotherapy (1 paper)Der Nervenarzt (1 paper)
- Partner nations
- GermanySwitzerland
In The Last Decade
Peter Rieckmann
12 papers receiving 92 citations
Peers
Comparison fields: 5 of 31
- Pathology and Forensic Medicine 85
- Oncology 28
- Genetics 10
- Neurology 12
- Developmental Neuroscience 3
Countries citing papers authored by Peter Rieckmann
This map shows the geographic impact of Peter Rieckmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Rieckmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Rieckmann more than expected).
Fields of papers citing papers by Peter Rieckmann
This network shows the impact of papers produced by Peter Rieckmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Rieckmann. The network helps show where Peter Rieckmann may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Rieckmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Multiple Sclerosis Therapy Consensus Group (MSTCG) Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations | 2008 | 47 |
| 2 | 2022 | 22 | |
| 3 | Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study | 2009 | 9 |
| 4 | Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS) | 2009 | 6 |
| 5 | 2022 | 5 | |
| 6 | Multiple Sclerosis Registry in Germany | 2008 | 3 |
| 7 | 2023 | 2 | |
| 8 | The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis | 2007 | 2 |
| 9 | Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study | 2011 | 1 |
| 10 | Juvenile growth and differentiation in naturally regenerated Norway spruce stands - consequences for silvicultural treatment | 2003 | 1 |
| 11 | 2001 | 1 | |
| 12 | MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study | 2009 | 1 |
| 13 | 2025 | 0 |
About Peter Rieckmann
Peter Rieckmann is a scholar working on Pathology and Forensic Medicine, Genetics, Hematology, Infectious Diseases and Nature and Landscape Conservation, having authored 13 papers that have together received 100 indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (9 papers), Chronic Lymphocytic Leukemia Research (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Forest Ecology and Biodiversity Studies (1 paper), Forest Management and Policy (1 paper), Systemic Sclerosis and Related Diseases (1 paper), Immunotherapy and Immune Responses (1 paper) and Acute Lymphoblastic Leukemia research (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (85 citations), Oncology (28 citations), Genetics (10 citations), Neurology (12 citations) and Developmental Neuroscience (3 citations). Peter Rieckmann has collaborated with scholars based in Germany and Switzerland. Frequent co-authors include Klaus V. Toyka, Heinz Wiendl, Ralf Gold, Reinhard Hohlfeld, Mathias Mäurer, Philipp Gulde, Sven G. Meuth, Mike P. Wattjes, Ralf A. Linker and Christoph Kleinschnitz. Their work appears in journals such as Stroke, JMIR Rehabilitation and Assistive Technologies, Journal of Neurology, Expert Opinion on Pharmacotherapy and Der Nervenarzt.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.